For example, the tyrosine kinase receptor HER2 is thought to be overexpressed in up to 30% of patients and is correlated with more aggressive cancer and subsequently increased mortality.92 There are currently a number of FDA‐approved monoclonal antibody treatments aimed at HER2, but they often need to be combined with chemotherapy which comprises the patient's immune system and is generally toxic to all cell types.93 Immunotherapy aimed at HER2 could provide an opportunity to create a robust antigen‐specific immune response capable of destroying the tumor without being toxic to other tissues. Here, ERBB2 is linked to neoplasm.